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CI

:   confidence interval

ctDNA

:   circulating tumor DNA

DFS

:   disease‐free survival

gDNA

:   genomic DNA

HER2

:   human epidermal growth factor receptor 2

HR

:   hormone receptor

IDC

:   infiltrating ductal carcinoma

IHC

:   immunohistochemistry

ILC

:   infiltrating lobular carcinoma

PFS

:   progression‐free survival

SNV

:   single‐nucleotide variant

TNBC

:   triple‐negative breast cancer

1. BACKGROUND {#cac212032-sec-0050}
=============

*TP53* is a tumor suppressor gene that plays a key role in many cellular pathways and regulates essential cell activities, such as proliferation, differentiation, cell death, DNA repair, and the formation of blood vessels \[[1](#cac212032-bib-0001){ref-type="ref"}, [2](#cac212032-bib-0002){ref-type="ref"}\]. Mutations in *TP53* are common in cancers \[[3](#cac212032-bib-0003){ref-type="ref"}, [4](#cac212032-bib-0004){ref-type="ref"}\] and present in approximately 25%‐30% of all breast cancer cases \[[5](#cac212032-bib-0005){ref-type="ref"}, [6](#cac212032-bib-0006){ref-type="ref"}\]. Several studies have investigated the *TP53* mutational spectrum in various subtypes of breast cancer \[[5](#cac212032-bib-0005){ref-type="ref"}, [6](#cac212032-bib-0006){ref-type="ref"}, [7](#cac212032-bib-0007){ref-type="ref"}, [8](#cac212032-bib-0008){ref-type="ref"}\]. However, the *TP53* genetic landscape in Chinese breast cancer patients remains unclear.

Numerous studies have indicated that *TP53* is a biomarker for predicting poor prognosis in breast cancer patients \[[5](#cac212032-bib-0005){ref-type="ref"}, [9](#cac212032-bib-0009){ref-type="ref"}, [10](#cac212032-bib-0010){ref-type="ref"}, [11](#cac212032-bib-0011){ref-type="ref"}\]. *TP53* mutations located in the regions encoded *TP53* DNA‐binding domains have been reported to be associated with poor prognosis in patients with breast cancer \[[10](#cac212032-bib-0010){ref-type="ref"}, [12](#cac212032-bib-0012){ref-type="ref"}\]. However, their predictive value for the efficacy of human epidermal growth factor receptor 2 (HER2)‐targeted therapy in breast cancer remains controversial. Several studies most of which relied upon immunohistochemistry (IHC) to assess p53 alterations have indicated that *TP53* mutations were not associated with the response to anticancer therapy \[[8](#cac212032-bib-0008){ref-type="ref"}, [13](#cac212032-bib-0013){ref-type="ref"}‐[16](#cac212032-bib-0016){ref-type="ref"}\]. Nevertheless, IHC cannot be used to detect all gene mutations, as many mutations do not lead to p53 protein accumulation. One early study indicated that p53 status, as determined by IHC, was not associated with the response to trastuzumab‐based treatment \[[15](#cac212032-bib-0015){ref-type="ref"}\]. However, two clinical studies have indicated that patients with *TP53* mutations exhibited good responses to trastuzumab \[[14](#cac212032-bib-0014){ref-type="ref"}, [17](#cac212032-bib-0017){ref-type="ref"}\]. Since most of the patients in these studies received chemotherapy in addition to trastuzumab, these findings must be confirmed by further studies.

In the present study, we used target region capture‐based next‐generation sequencing to analyze the *TP53* mutation spectrum of circulating tumor DNA (ctDNA) from 804 Chinese breast cancer patients and analyzed the relationships between *TP53* mutations, prognosis, and the efficacy of first‐line trastuzumab‐based therapy.

2. MATERIALS AND METHODS {#cac212032-sec-0060}
========================

2.1. Patients {#cac212032-sec-0070}
-------------

*TP53* mutation status was determined in the plasma of patients with metastatic breast cancer treated at National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (Beijing, China) between March 2015 and October 2018. The inclusion criteria were as follows: (1) patients who were at least 18 years old; (2) patients who had a histologic/cytologic diagnosis of invasive breast cancer; (3) patients who had received radical surgery for primay tumor; (4) patients who were female; (5) patients who had complete clinicopathological data; and (6) patients who had sufficient blood samples for ctDNA analysis. The exclusion criteria were as follows: (1) patients who were male; and (2) patients who had received chemotherapy within the past month before the peripheral blood samples collection. This study was approved by the Ethics Committee of National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (ref.: 16‐038/1117). All patients provided written informed consent.

To analyze the association between *TP53* mutations and trastuzumab responses, we retrospectively calculated the progression‐free survival (PFS) of human epidermal growth factor receptor 2‐positive (HER2^+^) patients who received trastuzumab (6 mg/kg every 3 weeks intravenously after an initial loading dose of 8 mg/kg until disease progress) combined with chemotherapy as first‐line therapy after being diagnosed with recurrent or metastatic breast cancer. Chemotherapy was chosen by the treating physician according to prior treatments and the patient\'s clinical characteristics. Patients were excluded if they had received previous targeted therapy, endocrine therapy, or any previous systemic chemotherapy for advanced disease. We did correlative analyses of PFS in patient subgroups based on combined chemotherapy drugs. Patietns who received trastuzumab combined with paclitaxel and docetaxel treatment were defined as taxane combination group; patients who received trastuzumab combined with capecitabine, vinorelbine, gemcitabine and cisplatin were defined as non‐taxane combination group.

We compared the *TP53* mutation frequency in our cohort with the MSK‐IMPACT cohort \[[18](#cac212032-bib-0018){ref-type="ref"}\]. The gene mutation status and clinical information of 1,746 patients with breast cancer were downloaded from the MSK‐IMPACT dataset using the cBioPortal database (<http://www.cbioportal.org>).

2.2. Blood sample collection {#cac212032-sec-0080}
----------------------------

The testing for patients was ordered by the treating physician to identify clinically relevant genomic alterations that could potentially help to determine prognosis or to make treatment decisions. Peripheral blood samples for ctDNA analysis were collected in Streck tubes (Streck, Omaha, NE, USA) and centrifuged (1,600 × *g* at 4°C for 10 min, followed by transfer to new microcentrifuge tubes, and centrifugation at 16,000 × *g* at 4°C for 10 min to remove remaining cell debris) within 72 hours to separate the plasma from the peripheral blood.

2.3. DNA extraction and quantification {#cac212032-sec-0090}
--------------------------------------

A QIAamp Circulating Nucleic Acid Kits (Qiagen, Hilden, Germany) was used to isolate circulating DNA from plasma samples. Genomic DNA (gDNA) was isolated from peripheral lymphocytes using the QIAamp DNA Blood Mini Kit (Qiagen) as a control. All DNA extractions were performed according to the manufacturer\'s protocols.

The DNA concentration was assessed using a Qubit fluorometer (Invitrogen, Carlsbad, CA, USA) and the Qubit dsDNA High‐sensitivity (HS) Assay Kit (Invitrogen). The size distribution of the circulating DNA was assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) and the DNA HS kit (Agilent Technologies).

2.4. Target capture and next‐generation sequencing {#cac212032-sec-0100}
--------------------------------------------------

Library preparation, hybrid capture, and circulating DNA and gDNA sequencing were performed as previously described \[[19](#cac212032-bib-0019){ref-type="ref"}, [20](#cac212032-bib-0020){ref-type="ref"}\]. The targeted region for sequencing covered ∼1.1 Mb, including 1,021 genes \[[21](#cac212032-bib-0021){ref-type="ref"}\], and encompassed all introns and exons of *TP53*. DNA sequencing was performed using the HiSeq 3000 Sequencing System (Illumina, San Diego, CA, USA) with 2 × 101 bp paired‐end reads.

Low‐quality reads and terminal adaptor sequences were filtered out. Burrows‐Wheeler Aligner (BWA, version 0.7.12‐r1039) was carried out to align the clean reads to the reference human genome (hg19), and Genome Analysis Toolkit (GATK, version 3.4‐46‐gbc02625) was used for realignment and recalibration. Single‐nucleotide variants (SNVs) were characterized by MuTect (version 1.1.4) and NChot \[[22](#cac212032-bib-0022){ref-type="ref"}\]. Small insertions and deletions (indels) were identified by GATK.

2.5. Follow‐up {#cac212032-sec-0110}
--------------

All patients were regularly followed‐up at the out‐patient clinic every 3 months within 2 years and every 6 months 2‐5 years after the surgery. The efficacy, safety, and survival data of advanced breast cancer patients were followed‐up every 2‐3 months. Last follow‐up time was October 30, 2018.

2.6. Statistical analysis {#cac212032-sec-0120}
-------------------------

The chi‐square test and Fisher\'s exact test were used to compare categorical variables. Disease‐free survival (DFS) was defined as the duration from radical resection of breast cancer to the time of recurrence or death of any cause. PFS was calculated from the date of treatment initiation to the date of disease progression or death of any cause. Patients without an endpoint (progression or death) were censored at the date of the last follow‐up. Kaplan‐Meier survival plots were generated based on gene mutation status, and curves were compared using log‐rank tests. A Cox proportional hazards model was used to analyze the association between DFS or PFS and gene mutations and clinical characteristics. All statistical tests used were two‐sided, and results with *P* values less than 0.05 were considered significant. All statistical analyses were performed using SPSS version 23.0 (IBM Corporation, Armonk, NY, USA) or GraphPad Prism 7.0 (GraphPad Software, La Jolla, CA, USA).

3. RESULTS {#cac212032-sec-0130}
==========

3.1. Patient characteristics {#cac212032-sec-0140}
----------------------------

A total of 804 female patients with metastatic breast cancer treated between March 2015 and October 2018 were retrospectively investigated. Patient characteristics are summarized in Table [1](#cac212032-tbl-0001){ref-type="table"}. The median age at which the patients were initially diagnosed with breast cancer was 42 years (range: 22 to 78 years) in all of the patients. The median age was 43 years (range: 22 to 78 years) in the *TP53* mutant group versus 42 years (range: 26 to 78 years) in the *TP53* wild‐type group (*P *= 0.568). Fifty‐five (6.8%) patients received trastuzumab plus chemotherapy as the first‐line treatment after being diagnosed with metastatic breast cancer.

###### 

Clinical characteristics of 804 patients with metastatic breast cancer

  Characteristic                                             Whole cohort \[cases (%)\]   *TP53* mutant \[cases (%)\]   *TP53* wild‐type \[cases (%)\]   *P* value
  ---------------------------------------------------------- ---------------------------- ----------------------------- -------------------------------- -----------
  Total                                                      804                          431                           373                              
  Menopausal status                                                                                                                                      
  Premenopausal                                              469 (58.3)                   247 (57.3)                    222 (59.5)                       0.526
  Postmenopausal                                             335 (41.7)                   184 (42.7)                    151 (40.5)                       
  Tumor stage at diagnosis                                                                                                                               
  Stage 1‐2                                                  495 (61.6)                   255 (59.2)                    240 (64.3)                       0.132
  Stage 3                                                    309 (38.4)                   176 (40.8)                    133 (35.7)                       
  Histology at diagnosis                                                                                                                                 
  ILC                                                        42 (5.2)                     23 (5.3)                      19 (5.1)                         0.877
  IDC                                                        762 (94.8)                   408 (94.7)                    354 (94.9)                       
  Molecular subtype                                                                                                                                      
  HR^+^/HER2^−^                                              397 (49.4)                   170 (39.4)                    227 (60.9)                       \<0.001
  HR^+^/HER2^+^                                              138 (17.2)                   69 (16.0)                     69 (18.5)                        
  HR^−^/HER2^+^                                              121 (15.0)                   84 (19.5)                     37 (9.9)                         
  HR^−^/HER2^−^                                              148 (18.4)                   108 (25.1)                    40 (10.7)                        
  HR status[^†^](#cac212032-tbl1-note-0001){ref-type="fn"}                                                                                               
  Positive                                                   535 (66.5)                   239 (55.5)                    296 (79.4)                       \<0.001
  Negative                                                   269 (33.5)                   192 (44.5)                    77 (20.6)                        
  HER2 status                                                                                                                                            
  Positive                                                   259 (32.2)                   153 (35.5)                    106 (28.4)                       0.032
  Negative                                                   545 (67.8)                   278 (64.5)                    267 (71.6)                       
  Line of chemotherapy                                                                                                                                   
  0                                                          16 (2.0)                     5 (1.2)                       11 (2.9)                         0.051
  1                                                          194 (24.1)                   96 (22.3)                     98 (26.3)                        
  ≥2                                                         594 (73.9)                   330 (76.6)                    264 (70.8)                       
  Line of endocrine therapy for HR^+^ patients                                                                                                           
  0                                                          221 (41.3)                   111 (46.4)                    110 (37.2)                       0.057
  1                                                          146 (27.3)                   64 (26.8)                     82 (27.7)                        
  ≥2                                                         168 (31.4)                   64 (26.8)                     104 (35.1)                       
  Line of anti‐HER2 therapy for HER2^+^ patients                                                                                                         
  0                                                          116 (44.8)                   76 (49.7)                     40 (37.7)                        0.057
  ≥1                                                         143 (55.2)                   77 (50.3)                     66 (62.3)                        

Positive HR status was defined as positive for estrogen receptor and/or progesterone receptor.

Abbreviations: HR, hormone receptor; HER2, human epidermal growth factor receptor 2; ILC, infiltrating lobular carcinoma; IDC, infiltrating ductal carcinoma.

John Wiley & Sons, Ltd.

3.2. Characterization of *TP53* mutations {#cac212032-sec-0150}
-----------------------------------------

We performed target region capture‐based next‐generation sequencing to evaluate the status of *TP53* mutations in the whole cohort. We found that 431 (53.6%) patients harbored at least one *TP53* mutation. Among them, 65 (15.1%) patients carried two different *TP53* mutations. The *TP53* mutations p.R213\*, p.R248Q, p.R273H, p.Y220C, and p.R175H were the top five mutations according to frequency and were present in 17 (3.9%), 15 (3.5%), 14 (3.2%), 12 (2.8%), and 11 (2.6%) patients, respectively. The majority of the mutations were missense mutations (55.7%), followed by frameshift (17.3%) and nonsense (15.4%) mutations. The distribution of mutations was nonuniform across the gene, with 75.1% of the mutations clustering in exons 5‐8, mostly spanning the sequence encoding the DNA‐binding domain. Exons 4 and 10 also harbored a substantial number of mutations, accounting for 10.4% and 4.2% of all mutations, respectively. Only 2.5% of the mutations were in exon 9, and the remaining 7.8% were in exon 3 and the intervening sequences (Supplementary Table S1).

3.3. Spectra of *TP53* mutations in different molecular subtypes {#cac212032-sec-0160}
----------------------------------------------------------------

*TP53* mutations were differentially distributed among different molecular subtypes of breast cancer (*P *\< 0.01; Figure [1A](#cac212032-fig-0001){ref-type="fig"}). *TP53* mutation frequency was lower in the patients with luminal‐type breast cancer (hormone receptor‐positive \[HR^+^\]HER2^+/−^; 44.7% \[239/535\];) than in the patients with HR^−^HER2^+^ breast cancer (69.4% \[84/121\]; *P *\< 0.001) and triple‐negative breast cancer (TNBC) (HR^−^HER2^−^; 73.0% \[108/148\]; *P *\< 0.001).

![Frequencies of *TP53* mutations in different molecular subtypes of breast cancer. A. Proportion of patients with *TP53* mutations according to molecular subtype. B. Comparison of *TP53* mutation frequencies between our data and the MSK‐IMPACT data. Abbreviations: HER2, human epidermal growth factor receptor 2; HR, hormone receptor](CAC2-40-260-g001){#cac212032-fig-0001}

Patients with HR^−^HER2^+^ tumors showed a higher proportion of span mutations as compared with non‐HR^−^HER2^+^ patients (17.1% \[18/105\] versus 8.0% \[33/414\]; *P *= 0.005), whereas those with HR^+^HER2^+^ cancer showed a higher proportion of missense mutations compared with patients with non‐HR^+^HER2^+^ cancer (67.1% \[51/76\] versus 53.7% \[238/443\]; *P *= 0.030). We did not find any differences in mutational hotspots among the molecular subtypes (*P *\> 0.05; Table [2](#cac212032-tbl-0002){ref-type="table"}).

###### 

*TP53* mutation characteristics in different molecular subtypes of breast cancer

  *TP53* mutation characteristic                       Total        HR^+^HER2^−^   HR^+^HER2^+^   HR^+^HER2^−^   HR^−^HER2^−^   *P* value
  ---------------------------------------------------- ------------ -------------- -------------- -------------- -------------- -----------
  Number of mutations                                  519          206            76             105            132            
  Variant classification \[number of mutations (%)\]                                                                            
  Missense                                             289 (55.7)   120 (58.3)     51 (67.1)      47 (44.8)      71 (53.8)      0.020
  Frame shift                                          90 (17.3)    27 (13.1)      11 (14.5)      21 (20.0)      31 (23.5)      0.072
  Nonsense                                             80 (15.4)    37 (18.0)      10 (13.2)      17 (16.2)      16 (12.1)      0.481
  Span                                                 51 (9.8)     16 (7.8)       4 (5.3)        18 (17.1)      13 (9.8)       0.028
  In‐frame Del/Ins                                     9 (1.7)      6 (2.9)        0 (0)          2 (1.9)        1 (0.8)        0.371
  Mutational hotspots \[number of mutations (%)\]                                                                               
  R213^\*^                                             17 (3.3)     9 (4.4)        1 (1.3)        5 (4.8)        2 (1.5)        0.291
  R248Q                                                15 (2.9)     7 (3.4)        1 (1.3)        1 (1.0)        6 (4.5)        0.196
  R273H                                                14 (2.7)     4 (1.9)        3 (3.9)        4 (3.8)        3 (2.3)        0.283
  Y220C                                                12 (2.3)     3 (1.5)        2 (2.6)        1 (1.0)        6 (4.5)        0.050
  R175H                                                11 (2.1)     4 (1.9)        3 (3.9)        2 (1.9)        2 (1.5)        0.648
  Others                                               450 (86.7)   179 (86.9)     66 (86.8)      92 (87.6)      113 (85.6)     \<0.001

Abbreviations: HR, hormone receptor; HER2, human epidermal growth factor receptor 2. Del, deletion; Ins, insertion.

John Wiley & Sons, Ltd.

We further compared the data in this study (from a Chinese cohort) with those from the MSK‐IMPAC cohort. A total of 1746 breast cancer patients from the MSK‐IMPACT cohort were included. Among them, 626 (35.9%) patients harbored *TP53* mutations. The frequency of *TP53* mutations in the Chinese cohort was significantly higher than that in the MSK‐IMPACT cohort (*P *\< 0.001). We further investigated the *TP53* mutation frequencies among different molecular subtypes and compared them between the Chinese and the MSK‐IMPACT cohorts. We observed significant differences between these two cohorts: in the HR^+^HER2^−^ subgroup, the *TP53* mutation frequency was higher in the Chinese cohort (*P *\< 0.001); in contrast, in the TNBC subgroup, the frequency of *TP53* mutation was higher in the MSK‐IMPACT cohort (*P *\< 0.001; Figure [1B](#cac212032-fig-0001){ref-type="fig"}).

3.4. Association of *TP53* mutation status and the DFS of breast cancer patients {#cac212032-sec-0170}
--------------------------------------------------------------------------------

To analyze the association between *TP53* mutation and DFS, we retrospectively calculated the DFS of the eligible patients. A total of 444 patients recorded DFS, including 243 (54.7%) patients with *TP53* mutations. We found that patients with *TP53* mutations had a shorter DFS than those with wild‐type *TP53*. The median DFS for patients with *TP53* mutations was 28.5 months (95% confidence interval \[CI\] = 23.6‐33.3 months) versus 40.6 months (95% CI = 33.5‐47.7 months) for patients without *TP53* mutations (hazard ratio = 1.32; 95% CI = 1.09‐1.61; *P *= 0.005; Figure [2](#cac212032-fig-0002){ref-type="fig"}).

![Kaplan‐Meier analyses of DFS in 444 patients with metastatic breast cancer. Abbreviations: DFS, disease‐free survival; CI, confidence interval](CAC2-40-260-g002){#cac212032-fig-0002}

The results of the univariate Cox regression analysis with clinical characteristics and *TP53* mutation status are shown in Table [3](#cac212032-tbl-0003){ref-type="table"}. HER2 status, HR status, tumor stage at diagnosis, histology at diagnosis, *TP53* mutation status, and exons 5‐8 mutation status were related to DFS of patients with metastatic breast cancer (all *P* \< 0.05). A multivariate Cox regression analysis was conducted to investigate the association between these characteristics and DFS. *TP53* mutation status was not significantly associated with DFS (hazard ratio = 1.18, 95% CI = 0.97‐1.45, *P* = 0.101). However, the DFS of patients with *TP53* mutations in exons 5‐8 was significantly shorter than the DFS of patients with wild‐type *TP53* (hazard ratio = 1.50, 95% CI = 1.11‐2.03, *P* = 0.009, Table [3](#cac212032-tbl-0003){ref-type="table"}).

###### 

Univariate and multivariate Cox regression analyses for DFS in patients with breast cancer

  Variable                                                                           Univariate Cox regression analysis   Multivariate Cox regression analysis                      
  ---------------------------------------------------------------------------------- ------------------------------------ -------------------------------------- ------------------ -------
  HER2 status (positive vs. negative)                                                1.42 (1.15‐1.77)                     0.001                                  1.28 (1.02‐1.60)   0.031
  HR status[^†^](#cac212032-tbl3-note-0001){ref-type="fn"} (positive vs. negative)   0.69 (0.56‐0.85)                     0.001                                  0.76 (0.62‐0.95)   0.015
  Tumor stage at diagnosis (stages 1‐2 vs. stage 3)                                  0.71 (0.59‐0.86)                     0.001                                  0.47 (0.24‐0.91)   0.005
  Histology at diagnosis (ILC vs. IDC)                                               0.46 (0.24‐0.88)                     0.020                                  0.76 (0.62‐0.92)   0.026
  *TP53* mutation status (mutation vs. wild‐type)                                    1.32 (1.09‐1.61)                     0.005                                  1.18 (0.97‐1.45)   0.101
  *TP53* exons 5‐8 mutation status (mutation vs. wild‐type)                          1.61 (1.20‐2.17)                     0.002                                  1.50 (1.11‐2.03)   0.009

Positive HR status was defined as positive for estrogen receptor and/or progesterone receptor.

Abbreviations: DFS, disease‐free survival; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; ILC, infiltrating lobular carcinoma; IDC, infiltrating ductal carcinoma.

John Wiley & Sons, Ltd.

3.5. Association of *TP53* mutation status and the response to first‐line trastuzumab‐based therapy in breast cancer patients {#cac212032-sec-0180}
-----------------------------------------------------------------------------------------------------------------------------

A total of 55 metastatic breast cancer patients who received trastuzumab‐based treatment as first‐line therapy were selected to evaluate the relationship between *TP53* mutation status and the response to trastuzumab. As shown in Supplementary Table S2, there were no significant differences in clinical characteristics between *TP53* mutant and wild‐type groups (all *P *\> 0.05). Additionally, *TP53* mutation status was not significantly associated with PFS. The median PFS for patients with *TP53* mutation was 9.1 months versus 5.4 months for those without *TP53* mutation (hazard ratio = 1.01; 95% CI = 0.59‐1.75; *P *= 0.966; Figure [3A](#cac212032-fig-0003){ref-type="fig"}).

![Impact of *TP53* mutation on the response to trastuzumab‐based first‐line therapy. A. PFS of patients underwent trastuzumab‐based first‐line treatment based on the presence of *TP53* mutation. B. PFS of patients in the taxane combination group based on the presence of *TP53* mutation. C. PFS of patients in the non‐taxane combination group based on the presence of *TP53* mutation. Abbreviations: PFS, progression‐free survival; CI, confidence interval](CAC2-40-260-g003){#cac212032-fig-0003}

To further explore the relationship between *TP53* mutation status and taxanes (including paclitaxel and docetaxel) treatment response in the breast cancer patients who received trastuzumab‐based treatment as first‐line therapy, we divided these patients into the taxane and non‐taxane combination groups (Supplementary Table S3). Interestingly, we found that in the taxane combination group, patients with *TP53* mutations had longer median PFS than those without *TP53* mutations (12.1 months vs. 2.7 months; hazard ratio = 0.08, 95% CI = 0.02‐0.30, *P *\< 0.001; Figure [3B](#cac212032-fig-0003){ref-type="fig"}). However, in the non‐taxane combination group, the opposite pattern was observed. Patients with *TP53* mutations had shorter median PFS than those with wild‐type *TP53* (4.1 months vs. 8.1 months, (hazard ratio = 4.84, 95% CI = 1.60‐14.66, *P = *0.005; Figure [3C](#cac212032-fig-0003){ref-type="fig"}).

4. DISCUSSION {#cac212032-sec-0190}
=============

In the present study, we performed a *TP53* mutation analysis within a large cohort of 804 Chinese patients with metastatic breast cancer and further compared our data to those from the MSK‐IMPACT cohort. Our results indicated that *TP53* mutation was a prognostic marker for poor outcomes in breast cancer. Additionally, it may affect the response of breast cancer patients to first‐line therapy based on trastuzumab.

In the present study, the frequency of *TP53* mutation was 53.6%, which was higher than that in the MSK‐IMPACT cohort (35.9%) \[[18](#cac212032-bib-0018){ref-type="ref"}\]. Additionally, our data indicated that the *TP53* mutation frequency was higher in TNBC and HER2^+^/HR^−^ breast cancer than in luminal‐type breast cancer. We also found that the frequency of *TP53* mutation in HER2^−^/HR^+^ breast cancer was higher in the MSK‐IMPACT cohort than in our cohort, while the opposite was true for the TNBC subgroup. Further study is needed to investigate these differences between cohorts. A striking feature of the patient cohort in the present study was that the median age at diagnosis was very young (42 years). This corresponds to increased proportions of HER2^+^ (32.2%) and TNBC (18.4%) patients in the study population. In addition, all patients in the study population had metastatic disease at the time of consent and blood drawn for the study. Moreover, most patients had received at least 2 lines of chemotherapy. It is our understanding that metastatic breast cancer are also associated with a higher frequency of *TP53* mutations than cancers at earlier stages. Both of these features of the patient population may have contributed to the higher percentage of *TP53* mutations found in this cohort when compared with that in the MSK‐IMPACT study. Another possibility is that this discrepancy reflects differences between the ethnicities of the patients.

Previous studies have shown that the *TP53* sequence encoding the DNA‐binding domain was the most frequently mutated region in the *TP53* gene in breast cancer \[[6](#cac212032-bib-0006){ref-type="ref"}, [8](#cac212032-bib-0008){ref-type="ref"}\]. Our study also found that most mutations occurred in the DNA‐binding domain and that p.R213\*, p.R248Q, p.R273H, p.Y220C, and p.R175H were common mutations of *TP53*. The majority (55.7%) of the mutations were missense mutations. Previous studies have shown that *TP53* mutation was a prognostic marker for poor breast cancer outcomes. Several studies have investigated the impact of different types of *TP53* somatic mutations on breast cancer, with conflicting results \[[5](#cac212032-bib-0005){ref-type="ref"}, [10](#cac212032-bib-0010){ref-type="ref"}, [12](#cac212032-bib-0012){ref-type="ref"}, [23](#cac212032-bib-0023){ref-type="ref"}, [24](#cac212032-bib-0024){ref-type="ref"}\]. Some studies \[[10](#cac212032-bib-0010){ref-type="ref"}, [12](#cac212032-bib-0012){ref-type="ref"}\] have shown that only missense mutations in the DNA‐binding domain affected the outcome of breast cancer patients, but this was not confirmed by other studies \[[10](#cac212032-bib-0010){ref-type="ref"}, [12](#cac212032-bib-0012){ref-type="ref"}, [24](#cac212032-bib-0024){ref-type="ref"}, [25](#cac212032-bib-0025){ref-type="ref"}\]. However, most previous studies have failed to investigate whether the prognostic impact of *TP53* mutation is independent of other clinicopathologic factors \[[10](#cac212032-bib-0010){ref-type="ref"}, [12](#cac212032-bib-0012){ref-type="ref"}, [24](#cac212032-bib-0024){ref-type="ref"}\]. In the present study, univariate Cox regression analysis indicated that *TP53* mutation was related to short DFS. However, in the multivariate analysis, *TP53* mutation status was not significantly associated with DFS. Further analysis showed that *TP53* mutation in exons 5‐8 was significantly associated with shorter DFS than wild‐type *TP53*. *TP53* mutations located in exons 5‐8 may predict shorter DFS of breast cancer patients than wild‐type *TP53*. Most of the *TP53* mutations found in breast cancer were missense substitutions located in the DNA binding domain (exons 5‐8). The difference in prognosis of *TP53* DNA‐binding domain mutations and mutations in other domains is still under debate. This difference is hypothesed to be related to the degree to which the mutants function as dominant negative mutants \[[24](#cac212032-bib-0024){ref-type="ref"}\]. However, this hypothesis needs to be confirmed by further studies.

Data on the association between the presence of *TP53* mutations and clinical treatment response are conflicting. Although a number of prior studies of breast cancer have suggested that the presence of *TP53* mutations was associated with a lack of response to a variety of chemotherapy agents, including anthracyclines and the combination of cyclophosphamide, methotrexate, and fluorouracil \[[8](#cac212032-bib-0008){ref-type="ref"}, [26](#cac212032-bib-0026){ref-type="ref"}, [27](#cac212032-bib-0027){ref-type="ref"}\], some other studies have found that *TP53* mutation was associated with a better response to docetaxel and trastuzumab \[[13](#cac212032-bib-0013){ref-type="ref"}, [14](#cac212032-bib-0014){ref-type="ref"}, [28](#cac212032-bib-0028){ref-type="ref"}, [29](#cac212032-bib-0029){ref-type="ref"}, [30](#cac212032-bib-0030){ref-type="ref"}\]. The association between *TP53* mutation and trastuzumab efficacy is also controversial. One early study indicated that p53 status, as determined by IHC, is not associated with the response to trastuzumab‐based treatment \[[15](#cac212032-bib-0015){ref-type="ref"}\]. Nevertheless, two clinical studies have indicated that patients with *TP53* mutations may exhibit a better response to trastuzumab \[[14](#cac212032-bib-0014){ref-type="ref"}, [17](#cac212032-bib-0017){ref-type="ref"}\]. However, trastuzumab is used in combination with chemotherapy in most cases during clinical practice. Therefore, we investigated the efficacy of trastuzumab in metastatic breast cancer. To reduce bias from other factors, we chose patients who received trastuzumab as first‐line therapy. We did not find any association between *TP53* mutation and the efficacy of trastuzumab‐based first‐line therapy. We further analyzed the impact of *TP53* mutation in different chemotherapy subgroups. Interestingly, we found that in the taxane combination group (including paclitaxel and docetaxel), the presence of *TP53* mutation was a sensitive biomarker of efficacy. In contrast, in the non‐taxane combination group, patients with *TP53* mutations exhibited a poor response. Different types of chemotherapeutics have different mechanisms of action, which may explain why patients with *TP53* mutations showed a better response to taxanes. A preclinical study indicated that in vitro, *TP53* mutant tumor cell lines are more sensitive to mitotic poisons, such as taxanes, than are wild‐type *TP53* cell lines, presumably because mutant cells lack the p53‐dependent capacity to induce G1 and G2 phase arrest and cannot defend themselves from taxane‐induced mitotic blockade and apoptosis \[[29](#cac212032-bib-0029){ref-type="ref"}\]. A phase III clinical trial assessed the impact of *TP53* status on taxane‐ and non‐taxane‐based chemotherapy regimens \[[31](#cac212032-bib-0031){ref-type="ref"}\]. However, this study showed no effect of *TP53* mutation on the response to taxane‐ and non‐taxane combination treatments. This may be because this study enrolled patients with all subtypes of breast cancer, and the impact of *TP53* mutation may be distinct for different subtypes of breast cancer. This study also enrolled locally advanced breast cancer patients who received neoadjuvant chemotherapy, and the dosage and intensity of chemotherapy are of crucial importance in inducing a response and a survival benefit in *TP53*‐mutated tumors \[[8](#cac212032-bib-0008){ref-type="ref"}\]. In our study, we investigated the impact of *TP53* mutation specifically in HER2^+^ patients who received first‐line trastuzumab‐based therapy. Another difference between the previous study and our study is that we used next‐generation sequencing to detect *TP53* mutations in ctDNA, which may limit the impacts of temporal and spatial heterogeneity among tumors.

Some limitations of this study must be acknowledged. First, DFS was retrospectively calculated, which may influence the survival analysis, as *TP53* mutation status may change after distant metastasis. Second, the retrospective design for the analysis of trastuzumab‐based first‐line therapy did not provide sufficient power to arrive at statistically sound conclusions. The predictive value of *TP53* mutation among different chemotherapy agents needs to be verified in prospective studies.

5. CONCLUSIONS {#cac212032-sec-0200}
==============

In conclusion, our data indicate that *TP53* somatic mutations are common in Chinese patients with breast cancer and are more frequently observed in HER2^+^/HR^−^ patients and those with TNBC than in those with other subtypes of breast cancer. *TP53* mutation in exons 5‐8 may be an independent prognostic marker for short DFS. *TP53* mutation has opposite effects in patients treated with trastuzumab‐based chemotherapy in combination with and without taxanes. Large‐scale prospective studies are needed to verify our findings.
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